S udden cardiac death (SCD) is a devastating and often unpredictable consequence of hypertrophic cardiomyopathy (HCM). [1] [2] [3] [4] [5] [6] [7] Nonsustained ventricular tachycardia (NSVT) on ambulatory ECG is recognized as 1 of 5 major risk markers for SCD in current management guidelines. 4, [8] [9] [10] [11] However, the prevalence and significance of NSVT may have been underestimated by relatively brief ambulatory monitoring, and the capability of NSVT as a marker for predicting SCD, including whether the rate, length, and frequency of NSVT are relevant remain incompletely resolved.
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evident. 1 The Tufts Medical Center Institutional Review Board approved this retrospective chart review.
Ambulatory Electrocardiographic Monitoring
Of the 160 ICD study patients, 94 had a 24-or 48-hour ambulatory ECG performed prior to implant obtained for the purpose of risk stratification. Ambulatory monitoring was not performed in 66 patients because the decision to implant an ICD had been made based on other high-risk features. The only clinical difference between those undergoing ambulatory monitoring was a lower LV ejection fraction in those not undergoing ambulatory monitoring (60.2±10.8 versus 65.1±6.4; P=0.0013; Tables I-III in the Data Supplement). NSVT was defined as ≥3 consecutive ventricular beats at a rate of >120 beats per minute. The number of beats, rate, and frequency of NSVT runs on ambulatory ECG were analyzed.
ICD Interrogation
At Tufts Medical Center, ICD patients had standard device interrogations at ≈3-month intervals, via on-site visit or remote transtelephonic follow-up. Rate cutoff criteria for detection/therapy of ventricular tachyarrhythmia were programmed at the discretion of the managing electrophysiologist. The average monitor zone was set at 173±19 beats per minute. The average VT zone was 202±13 beats per minute. The average VF zone was set at 233±13 beats per minute. As with ambulatory ECG, NSVT on ICD interrogation was defined as ≥3 beats at a heart rate >120 beats per minute. All episodes of NSVT, VT, and VF achieving ICD detection criteria were reviewed and confirmed by a staff electrophysiologist (Dr Link). The time and date of each NSVT was documented. The number of consecutive ventricular beats and rate of each run of NSVT were measured.
End Points
The primary outcome measure was the occurrence of ICD-treated ventricular tachyarrhythmias, including antitachycardia pacing therapies and ICD shocks. In patients experiencing multiple end points, the first treated ventricular arrhythmia was considered the primary outcome. Survival data by December 2015 were collected by chart and electronic record review.
Statistical Analysis
Clinical data were analyzed as means with standard deviations (or medians with 25th and 75th percentiles) for continuous variables and frequencies with proportions for categorical variables. Continuous variables were compared using 2-sample t tests when normally distributed or Wilcoxon rank-sum tests for skewed data. Categorical variables were compared by χ 2 test or Fisher's exact test. Arrhythmia profiles were censored at the time of the first appropriate ICD intervention.
To investigate the association between the presence of NSVT and primary outcome, the first occurrence of NSVT (either on ambulatory monitoring or ICD interrogation) was considered as a time-dependent covariate and coded as present or absent. Cox proportional hazard models were used in the time-to-event analysis to examine the association between NSVT and the primary end point.
To investigate the prognostic value of the rate, length, and frequency of NSVT, the NSVT variable was further dichotomized into (1) slow (≤200 beats per minute) or fast (>200 beats per minute); (2) short (≤7 beats) or long (>7 beats); and (3) single (1 run) or repetitive (>1 runs). The first occurrence of fast NSVT and long NSVT and the second occurrence of NSVT were considered as time-dependent covariates. Cox proportional hazards models were used in the timeto-event analyses to examine the associations between the presence of fast, long, and repetitive NSVT and the primary end point.
Age, sex, maximum LV thickness, LV ejection fraction, history of cardiac arrest, history of syncope, family history of SCD, history of coronary artery disease, history of septal myectomy or alcohol septal ablation, and blood urea nitrogen were adjusted in multivariate analyses. The consistency of detecting NSVT between ambulatory monitor and ICD interrogation was assessed by inter-rater agreement test. Survival was estimated using Kaplan-Meier curve and compared using log-rank test. A 2 sided P value <0.05 was considered statistically significant. SAS 9.4 was used to perform all statistical analysis. (Table 1) . LV wall thickness were 10 to 40 mm (mean 20.7±6.2). Eighty (50%) had an LV outflow tract gradient ≥30 mm Hg at rest or with physiological (exercise) provocation.
Results

Baseline Clinical Characteristics
ICDs were implanted in 5 patients (3%) for secondary prevention after cardiac arrest with documented VF or sustained VT, while the other 155 patients were implanted for primary prevention based on the American College of Cardiology/ American Heart Association risk model. 4 The distribution of 5 conventional risk markers for SCD was unexplained syncope (n=47), family history of SCD (n=44), maximum LV wall thickness ≥30 mm on echocardiography (n=22), presence of NSVT (n=47), and hypotensive blood pressure response to exercise (n=13).
Patients received the following cardioactive medications: β-blockers (n=116), calcium channel blockers (n=53), and antiarrhythmic medications, including amiodarone (n=13), sotalol (n=9), disopyramide (n=7), dofetilide (n=3), and flecainide, propafenone, and mexiletine (n=1 each). The indications for administration of antiarrhythmic medications were largely atrial fibrillation (n=24) and ventricular arrhythmia (n=4).
Detection of NSVT
A total of 86 patients (54%) had NSVT detected, including 39 before implant on ambulatory ECG, 44 on ICD interrogation, and 22 on both ( Figure 1 ). The rate of the NSVT detected on ambulatory monitoring was <170 beats per minute in the 27 of the 39 patients in whom rate of NSVT was documented. Of the 55 patients without NSVT on ambulatory monitoring, NSVT was subsequently detected on ICD interrogation in 21
WHAT IS KNOWN
• Nonsustained ventricular tachycardia (NSVT) is 1 of the 5 major risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy.
WHAT THE STUDY ADDS
• Faster runs of NSVT (>200 beats per minute) are more predictive of implantable cardioverter defibrillator (ICD)-treated arrhythmias than slower runs of NSVT.
• Longer runs of NSVT (>7 beats) are more predictive of ICD-treated arrhythmias than shorter runs of NSVT.
• Repetitive runs of NSVT are more predictive of ICD-treated arrhythmias than a single run of NSVT.
patients (38%). Agreement of NSVT detection between ambulatory Holter ECG and ICD interrogation was poor (κ=0.18).
Ambulatory ECG monitoring detected a mean of 2 (range 1-7) runs of NSVT, with a mean number of 11 beats (range 3-51) and mean rate of 152 beats per minute (range 120-192). On ICD interrogation, a mean number of 6.5 runs of NSVT (range 1-41) were detected, with a mean number of 14 beats (range 4-80) at a mean rate of 222 beats per minute (range 174-350 beats per minute).
NSVT-and ICD-Treated Ventricular Arrhythmias
The interval from ICD implant to first device therapy was 3.72 (0.01-13.61) years; time of implant to end of follow-up was 4.0 (0.62, 13.6) years. During follow-up, 24 patients (15%) experienced primary outcomes, that is, ICD-treated ventricular tachyarrhythmias, including antitachycardia pacing for VT (n=10) and ICD shocks for VT/VF (n=14; Table 2 ).
Eighteen of 86 patients (21%) in whom NSVT was detected experienced primary outcomes, compared with 6 of 74 patients (8%) without NSVT (P=0.024; Figure 2 The survival probability for freedom from implantable cardioverter defibrillator (ICD)-treated ventricular arrhythmias stratified by the presence of nonsustained ventricular tachycardia (NSVT). Survival was estimated using Kaplan-Meier curves and compared using log-rank test. NSVT in Hypertrophic Cardiomyopathy NSVT with runs of >7 beats was significantly associated with ICD-treated VT/VF in both univariable (HR, 4.65; 95% CI, 1.72-12.57; P=0.0024) and multivariable (HR, 5.66; 95% CI, 1.81-17.65; P=0.0028) analyses, while shorter NSVT bursts with <7 beats were not (Figure 4 ). Repetitive NSVT (>1) was significantly associated with ICD-treated VT/VF in both univariable (HR, 4.49; 95% CI, 1.67-12.04; P=0.0028) and multivariable (HR, 7.27; 95% CI, 2.11-25.07; P=0.0017) analyses, while single runs of NSVT were not (Table 4 and Figure 5 ).
Discussion
Asymptomatic NSVT has been an acknowledged SCD risk factor in HCM for 35 years. 4, 8, [11] [12] [13] [14] However, periodically, questions have been raised concerning the strength and specifics of NSVT as a marker for determining level of risk in individual patients and targeting candidates for primary prevention ICDs. The present study comprised 160 HCM patients judged by their managing cardiologist to be at unacceptably high risk based on the American College of Cardiology/American Heart Association HCM guidelines for risk stratification. NSVT was significantly associated with the end point of ICD interventions for arrhythmias, and most importantly, faster rates >200 beats per minute, longer (>7 beats) and repetitive bursts of NSVT predicting a greater likelihood of ICD-treated ventricular tachyarrhythmias, while slower, shorter, and single runs of VT did not. These data demonstrate that not all NSVT runs have the same predictive power, possibly accounting for the discrepancies in prior studies regarding the ability of NSVT on ambulatory monitoring to predict subsequent SCD events and ventricular tachyarrhythmias.
Indeed, although it is perhaps intuitive to place greater weight on frequent, longer, and faster episodes of NSVT, BUN indicates blood urea nitrogen; CAD, coronary artery disease; CI, confidence interval; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HR, hazard ratio; ICD, implantable cardioverter defibrillator; LA, left atrium; LV, left ventricle; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association; SCD, sudden cardiac death; WT, wall thickness; and y, year.
*Adjusted for age, sex, maximum LV WT, LV EF, history of cardiac arrest, history of syncope, family history of SCD, CAD, history of septal myectomy/alcohol septal ablation, BUN, β-blocker use, and calcium channel blocker use.
†The association between NSVT on ambulatory Holter ECG, and treated ventricular arrhythmias was examined among patients who had ambulatory Holter ECG (n=94).
‡Obstructive HCM: left ventricular outflow tract gradients >30 mm Hg at rest or with provocation. NSVT in Hypertrophic Cardiomyopathy there have been no prior systematic investigations focused on whether the number, duration, and rate of NSVT episodes impact SCD risk. 4, 7 Because of the low event rate of SCD in unselected HCM populations, some previous studies may have lacked the power to convincingly associate NSVT with SCD. 8, 12, 13, [15] [16] [17] Our study is the first to demonstrate that fast, long, and repetitive NSVT is more predictive than slow, short, and isolated NSVT.
NSVT has been reported in ≈20% to 35% of HCM patients usually with 24-to 48-hour ambulatory ECG monitoring and considered standard practice for HCM risk stratification. 4, 7 In our study, with the use of extended ICD monitoring to investigate NSVT in HCM patients, we found, in comparison to prior studies, a much higher prevalence of >50%. Because the ICD monitors heart rhythm over a much longer frame of time than ambulatory ECG, it provides a greater opportunity to capture NSVT episodes and represents a more accurate representation of the burden and significance of NSVT in this population. However, because the ICD was programmed to record ventricular activity only when the rate was above a threshold (mean in this study of 170 beats per minute), slower NSVT could be missed, resulting in underestimation. We think that the data presented here merit consideration for extended monitoring of NSVT in HCM patients. In particular, 24-to 48-hour monitoring may be considered not sufficient to adequately assess arrhythmic risk.
NSVT is a recognized risk marker for SCD in HCM patients based on characteristically brief runs recorded by . Survival probability for freedom from first implantable cardioverter defibrillator (ICD)-treated ventricular tachyarrhythmia stratified by the rate of nonsustained ventricular tachycardia (NSVT; ≤200 vs >200 beats per minute) in 66 patients. Survival was estimated using Kaplan-Meier curves and compared using log-rank test. . Survival probability for freedom from first implantable cardioverter defibrillator (ICD)-treated ventricular tachyarrhythmia stratified by length of nonsustained ventricular tachycardia (NSVT; ≤7 vs >7 beats) in 79 patients. Survival was estimated using Kaplan-Meier curves and compared using log-rank test.
ambulatory monitoring, particularly in individuals <30 years of age.
14 However, there are conflicting data regarding the capability of NSVT to predict SCD in individual patients. Early studies of referral-based populations showed a significant association between NSVT and SCD, 10 while community-based studies (less selected for high-risk patients) failed to replicate the strength of this association, presumably due in part to a lower event rate of SCD. 2, 3, 15 There is a concern regarding the association between the number of runs of NSVT and the outcome. Even if the occurrence of NSVT is totally random and not related to the outcome at all, an association may still be observed simply because patients with longer follow-up duration have more chance of being observed additional NSVT runs. However, there is no significant difference in the follow-up durations: 3.8 (interquartile range 1.2-7.1) years in patients with 1 run and 4.4 (interquartile range 2.6-7.0) years in patients with multiple runs (P value of Wilcoxon rank-sum test =0.3133). The interval between first and second NSVT was 0.58 (interquartile range 0.17-1.24) years. It appeared that NSVT tends to recur shortly after the first episode if it were to recur. Therefore, we think that this methodological issue is unlikely to invalidate the finding of our study (Table IV in 
Conclusions
NSVT occurs with high frequency in HCM patients over extended ICD monitoring periods. NSVT was independently associated with appropriate ICD interventions, and in particular, faster, longer, and repetitive runs of NSVT were highly predictive of ICD-treated VT/VF. These data emphasize the importance of NSVT as an SCD risk predictor in HCM and provide evidence to merit consideration of extended monitoring for NSVT in HCM patients.
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